Vish Muthusamy, PhD
Research & Publications
Biography
News
Research Summary
I direct the Center for Precision Cancer Modeling (CPCM), which is a research center and core facility sponsored by the Yale Cancer Center to further preclinical development of cancer therapies. My primary research interests include development of therapeutic approaches majorly directed against cancer. I am also interested in development and pharmacological improvement of drugs against other pathological states such as auto-immune and infectious diseases. I have expertise in development of sophisticated in vivo models and utilize these to understand and target the molecular and cellular mechanisms that drive cancer progression. Through the core, I help advance candidate drugs for Yale Investigators from discovery through preclinical stage and set the stage for them to be approved as experimental drugs in clinical trials. Several drugs that I helped develop are currently in various stages of clinical testing.
Coauthors
Selected Publications
- Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses.Jiang X, Muthusamy V, Fedorova O, Kong Y, Kim DJ, Bosenberg M, Pyle AM, Iwasaki A. Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses. The Journal Of Experimental Medicine 2019, 216: 2854-2868. PMID: 31601678, PMCID: PMC6888973, DOI: 10.1084/jem.20190801.
- Neutralization of Pathogenic Fungi with Small-Molecule Immunotherapeutics.Chirkin E, Muthusamy V, Mann P, Roemer T, Nantermet PG, Spiegel DA. Neutralization of Pathogenic Fungi with Small-Molecule Immunotherapeutics. Angewandte Chemie (International Ed. In English) 2017, 56: 13036-13040. PMID: 28793176, DOI: 10.1002/anie.201707536.
- Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor.Rullo AF, Fitzgerald KJ, Muthusamy V, Liu M, Yuan C, Huang M, Kim M, Cho AE, Spiegel DA. Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor. Angewandte Chemie (International Ed. In English) 2016, 55: 3642-6. PMID: 26879524, PMCID: PMC5597302, DOI: 10.1002/anie.201510866.
- DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR.Micevic G, Muthusamy V, Damsky W, Theodosakis N, Liu X, Meeth K, Wingrove E, Santhanakrishnan M, Bosenberg M. DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell Reports 2016, 14: 2180-2192. PMID: 26923591, PMCID: PMC4785087, DOI: 10.1016/j.celrep.2016.02.010.